Arcus Biosciences (RCUS) is back in focus after reporting second quarter 2026 results, with revenue of US$41 million and a net loss of US$91 million, alongside fresh full year revenue guidance.

Against this backdrop, Arcus Biosciences shares have shown building momentum, with a 16.07% 90 day share price return and a 24.35% year to date share price return, while the 1 year total shareholder return is very large.

If this earnings update has you looking beyond a single stock, it could be a good moment to see what else is moving in cancer and biotech related AI, starting with 43 healthcare AI stocks

Bulls point to Arcus Biosciences’ pipeline and recent share price strength, while bears highlight shrinking revenue and sizeable losses. As you weigh what the market is already pricing in, which side does the current valuation lean toward?

Most Popular Narrative: 24% Undervalued

The most followed narrative currently pins Arcus Biosciences at a fair value of $38, compared with the last close at $28.96, which frames the stock as materially undervalued and leans heavily on what its kidney cancer pipeline could mean for future cash flows under a 7.47% discount rate.

Arcus Biosciences is prioritizing the launch of its late-stage development program for the HIF-2 alpha inhibitor, casdatifan, which has shown significant efficacy differentiation relative to existing market competitors. This could enhance future revenue through competitive advantage in the RCC market.

Curious what sits behind that $38 fair value for Arcus Biosciences. The narrative focuses on potential revenue expansion, margin uplift and a rich future earnings multiple. The exact hurdle rates and profit assumptions might surprise you. The full story connects those projections directly back to today’s price.

Result: Fair Value of $38 (UNDERVALUED)

However, there are still clear watchpoints, including potential regulatory setbacks for casdatifan or domvanalimab, as well as stronger competition in renal cell carcinoma that could challenge the Arcus Biosciences upside case.

Another View: What Multiples Say About Arcus Biosciences

That $38 fair value for Arcus Biosciences leans heavily on future cash flow assumptions. On current numbers the stock trades on a P/S of 31.5x, compared with 11.1x for the US Biotechs industry and 8.7x for peers, and a fair ratio of just 0.2x. Is this a mispricing or a sign that expectations are running very hot?

For a clearer sense of how this pricing gap could matter in practice, including where the fair ratio suggests the market could move over time, See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

With both risks and rewards in play for Arcus Biosciences, sentiment is far from one sided, so move quickly, review the details, and weigh the 2 key rewards and 3 important warning signs

Looking for more investment ideas beyond Arcus Biosciences?

If Arcus Biosciences has sharpened your focus, do not stop here. Fresh ideas often appear where you least expect them, so keep expanding your watchlist.

• Target potential mispricings by scanning 49 high quality undervalued stocks that combine appealing fundamentals with room for a stronger market view.
• Strengthen your portfolio core by reviewing the solid balance sheet and fundamentals stocks screener (49 results) to spot companies that may better handle financial pressure.
• Get in early on quieter opportunities by checking the screener containing 20 high quality undiscovered gems that other investors might not be tracking yet.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.